Inflammatory carcinoma of the breast and drugs of ingredients of ezetimibe; simvastatin - a phase IV clinical study of FDA data


Summary:

Inflammatory carcinoma of the breast is reported only by a few people who take drugs with ingredients of ezetimibe; simvastatin. This phase IV clinical study analyzes 20,181 people who have side effects while taking drugs with ingredients of ezetimibe; simvastatin from the the FDA. Among them, 4 have Inflammatory carcinoma of the breast. Find out below who they are, when they have Inflammatory carcinoma of the breast and more.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Ezetimibe and simvastatin, Ezetimibe; simvastatin, Vytorin.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.


On Dec, 02, 2022

20,181 people reported to have side effects when taking drugs with ingredients of ezetimibe; simvastatin.
Among them, 4 people (0.02%) have Inflammatory carcinoma of the breast


What is Inflammatory carcinoma of the breast?

Inflammatory carcinoma of the breast is found to be associated with 156 drugs and 82 conditions by eHealthMe.

Number of reports submitted per year:

Could drugs with ingredients of ezetimibe; simvastatin cause Inflammatory carcinoma of the breast?

Time on drugs with ingredients of ezetimibe; simvastatin when people have Inflammatory carcinoma of the breast *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 100 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Inflammatory carcinoma of the breast when taking drugs with ingredients of ezetimibe; simvastatin *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Inflammatory carcinoma of the breast when taking drugs with ingredients of ezetimibe; simvastatin *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 100 %
  • 60+: 0.0 %

Conditions people have *:

  1. Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 4 people, 100.00%

Other drugs people take *:

  1. Metoprolol Tartrate: 2 people, 50.00%
  2. Enalapril Maleate: 2 people, 50.00%
  3. Aspirin: 1 person, 25.00%

Other side effects people have besides Inflammatory carcinoma of the breast *:

  1. Metastases To Spine (cancer spreads to spine): 4 people, 100.00%
  2. Metastases To Lung (cancer spreads to lung): 4 people, 100.00%
  3. Metastases To Liver (cancer spreads to liver): 4 people, 100.00%
  4. Hair Loss: 3 people, 75.00%
  5. Cellulitis (infection under the skin): 3 people, 75.00%
  6. Breast Cancer Metastatic: 3 people, 75.00%
  7. Metastases To Central Nervous System (cancer spreads to central nervous system): 2 people, 50.00%
  8. Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 2 people, 50.00%
  9. Cerebellar Tumor: 2 people, 50.00%
  10. Neck Pain: 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.


How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drugs with ingredients of ezetimibe; simvastatin, their effectiveness, alternatives and more:

How the study uses the data?

The study uses data from the FDA. It is based on ezetimibe; simvastatin. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: